Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia

利用α-酮戊二酸依赖性代谢来治疗急性髓系白血病

基本信息

  • 批准号:
    10523632
  • 负责人:
  • 金额:
    $ 20.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-17 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Therapeutic modulation of dysregulated metabolism has emerged as a successful therapeutic strategy for acute myeloid leukemia (AML) harboring oncogenic isocitrate dehydrogenase (IDH) mutations. Inhibition of IDH results in terminal myeloid differentiation of leukemic blasts and led to FDA-approval of IDH1 and IDH2 inhibitors in AML. However, there are currently no metabolism-directed therapies for IDH wild-type AML, which represents the majority of AML patients. Preliminary data presented in this proposal describe the identification of 2- oxoglutarate dehydrogenase (OGDH), a tricarboxylic acid (TCA) cycle enzyme which catalyzes the conversion of alpha-ketoglutarate (aKG) to succinyl CoA, as a previously unknown metabolic vulnerability in AML. Inhibition of this enzyme is sufficient to upregulate cellular aKG and drive myeloid differentiation in AML cells lacking IDH mutations. Currently however, the molecular mechanisms facilitating the change in cell fate with OGDH inhibition remain unknown, as do the genotypic contexts where exploiting aKG-dependent metabolism is most efficacious. The studies proposed seek to rigorously test the hypotheses that, 1) the treatment-refractory TP53- mutant/complex karyotype (CK) AML subset may be particularly sensitive to aKG perturbation, and 2) that the TET family of aKG-dependent dioxygenases which convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and impact gene expression, among other chromatin modifying enzymes, serve as effectors of aKG- dependent differentiation. The research plan will utilize in vitro systems to characterize the aKG-dependent epigenetic program, in vivo mouse models to examine OGDH as a putative target in TP53-mutant/CK AML, and patient samples/patient-derived xenografts to determine if aberrant aKG-dependent metabolism sustains human leukemia. The proposed investigations will expand our biological understanding of metabolite use in leukemia and advance a differentiation-based strategy to treat chemotherapy-refractory leukemias that lack conventionally targetable oncogenes. The applicant, Dr. Scott Millman, an Instructor on the Leukemia Service at the Memorial Sloan Kettering Cancer Center (MSKCC), has devised a 5-year career development plan that builds upon his background in molecular biology and biochemistry, and his clinical training in medical oncology. Dr. Millman will conduct the proposed research under the mentorship of Dr. Scott Lowe, an internationally renowned expert in cancer genetics with a proven track record of training successful independent investigators, to develop new skills in functional genomics and leukemia modeling that are essential for his career goal of developing new therapeutic approaches for hematologic malignancies. This mentorship, combined with the ideal training environment provided at MSKCC, will allow Dr. Millman to carry out the proposed research program and transition to an R01- funded independent, physician-scientist position in an academic setting.
项目总结/摘要 代谢失调的治疗性调节已经成为急性胰腺炎的成功治疗策略。 携带致癌异柠檬酸脱氢酶(IDH)突变的髓性白血病(AML)。IDH抑制结果 在白血病原始细胞的终末髓样分化中,并导致FDA批准IDH 1和IDH 2抑制剂, 急性髓细胞白血病然而,目前还没有针对IDH野生型AML的代谢导向疗法,这代表了 大多数AML患者。本提案中提供的初步数据描述了2- 氧代戊二酸脱氢酶(OGDH),一种三羧酸(TCA)循环酶,其催化戊二酸的转化, α-酮戊二酸(aKG)转化为琥珀酰CoA,作为AML中以前未知的代谢脆弱性。抑制 这种酶足以上调细胞aKG并驱动缺乏IDH的AML细胞的髓样分化 突变。然而,目前,促进OGDH抑制改变细胞命运的分子机制 仍然未知,因为利用aKG依赖性代谢最有效的基因型背景也是如此。 提出的研究试图严格检验以下假设:1)难治性TP 53- 突变/复杂核型(CK)AML亚群可能对aKG扰动特别敏感,2)突变/复杂核型(CK)AML亚群可能对aKG扰动特别敏感, 将5-甲基胞嘧啶(5 mC)转化为5-羟甲基胞嘧啶的aKG依赖性双加氧酶的泰特家族 (5 hmC)和影响基因表达,以及其他染色质修饰酶,作为aKG的效应子。 依赖分化该研究计划将利用体外系统来表征aKG依赖性 表观遗传学程序,体内小鼠模型,以检查OGDH作为TP 53突变体/CK AML中的推定靶标,以及 患者样本/患者来源的异种移植物,以确定异常aKG依赖性代谢是否维持人类 白血病拟议的调查将扩大我们的代谢物在白血病中使用的生物学理解 并提出一种基于分化的策略来治疗化疗难治性白血病, 靶向癌基因申请人斯科特·米尔曼博士是纪念医院白血病服务的指导员 斯隆凯特琳癌症中心(MSKCC),设计了一个5年的职业发展计划,建立在他的基础上, 分子生物学和生物化学的背景,以及他在医学肿瘤学方面的临床训练。米尔曼医生会 进行拟议的研究的指导下博士斯科特劳,一个国际知名的专家, 癌症遗传学,在培训成功的独立研究人员方面有着良好的记录, 在功能基因组学和白血病建模,这是必不可少的,他的职业目标,开发新的治疗 血液恶性肿瘤的治疗方法。这种指导,结合理想的培训环境, 在MSKCC提供,将允许米尔曼博士进行拟议的研究计划,并过渡到R 01- 在学术环境中获得资助的独立的医生科学家职位。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott Evan Millman其他文献

Scott Evan Millman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott Evan Millman', 18)}}的其他基金

Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia
利用α-酮戊二酸依赖性代谢来治疗急性髓系白血病
  • 批准号:
    10684842
  • 财政年份:
    2022
  • 资助金额:
    $ 20.61万
  • 项目类别:

相似海外基金

Energy-efficient biochemistry for biological carbon capture and re-use
用于生物碳捕获和再利用的节能生物化学
  • 批准号:
    491396-2015
  • 财政年份:
    2015
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Banting Postdoctoral Fellowships Tri-council
Biochemistry and biological function of Dnmt2 methyltransferases
Dnmt2甲基转移酶的生物化学和生物学功能
  • 批准号:
    221538490
  • 财政年份:
    2012
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Research Units
FOR 1530: Anaerobic Biological Dehalogenation: Organisms, Biochemistry and (Eco-)Physiology
FOR 1530:厌氧生物脱卤:有机体、生物化学和(生态)生理学
  • 批准号:
    171475307
  • 财政年份:
    2011
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Research Units
Biochemistry and biological function of Dnmt2 methyltransferases
Dnmt2甲基转移酶的生物化学和生物学功能
  • 批准号:
    119070637
  • 财政年份:
    2009
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Research Units
FOR 1082: Biochemistry and Biological Function of Dnmt2 Methyltransferases
FOR 1082:Dnmt2 甲基转移酶的生物化学和生物学功能
  • 批准号:
    65636347
  • 财政年份:
    2009
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Research Units
Biochemistry and biological function of mammalian Dnmt1
哺乳动物Dnmt1的生物化学和生物学功能
  • 批准号:
    5370244
  • 财政年份:
    2002
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Priority Programmes
Biochemistry and biological function of mammalian Dnmt1
哺乳动物Dnmt1的生物化学和生物学功能
  • 批准号:
    5370240
  • 财政年份:
    2002
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Priority Programmes
The basic research on keep of freshness of garden crop (Physiology and biochemistry and molecularly-biological approach for aging and de-greening of the garden crop)
园林作物保鲜基础研究(园林作物老化脱绿的生理生化及分子生物学方法)
  • 批准号:
    12660030
  • 财政年份:
    2000
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
BIOCHEMISTRY AND MOLECULAR BIOLOGICAL
生物化学和分子生物学
  • 批准号:
    2378046
  • 财政年份:
    1997
  • 资助金额:
    $ 20.61万
  • 项目类别:
BIOCHEMISTRY AND MOLECULAR BIOLOGICAL
生物化学和分子生物学
  • 批准号:
    2160531
  • 财政年份:
    1996
  • 资助金额:
    $ 20.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了